Cardiff Oncology Stock Performance
| CRDF Stock | USD 2.59 0.07 2.63% |
On a scale of 0 to 100, Cardiff Oncology holds a performance score of 5. The firm shows a Beta (market volatility) of 1.1, which signifies a somewhat significant risk relative to the market. Cardiff Oncology returns are very sensitive to returns on the market. As the market goes up or down, Cardiff Oncology is expected to follow. Please check Cardiff Oncology's sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether Cardiff Oncology's price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cardiff Oncology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent fundamental indicators, Cardiff Oncology reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 16.3 M |
Cardiff |
Cardiff Oncology Relative Risk vs. Return Landscape
If you would invest 221.00 in Cardiff Oncology on September 5, 2024 and sell it today you would earn a total of 38.00 from holding Cardiff Oncology or generate 17.19% return on investment over 90 days. Cardiff Oncology is currently generating 0.4184% in daily expected returns and assumes 5.7542% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Cardiff, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardiff Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiff Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cardiff Oncology, and traders can use it to determine the average amount a Cardiff Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0727
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRDF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.75 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Cardiff Oncology is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardiff Oncology by adding it to a well-diversified portfolio.
Cardiff Oncology Fundamentals Growth
Cardiff Stock prices reflect investors' perceptions of the future prospects and financial health of Cardiff Oncology, and Cardiff Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardiff Stock performance.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (76.37) % | ||||
| Current Valuation | 80.03 M | ||||
| Shares Outstanding | 51.13 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 2.75 X | ||||
| Price To Sales | 197.70 X | ||||
| Revenue | 488 K | ||||
| EBITDA | (45.01 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (30.89 M) | ||||
| Earnings Per Share | (0.95) X | ||||
| Total Asset | 81.64 M | ||||
| Retained Earnings | (339.54 M) | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
About Cardiff Oncology Performance
By analyzing Cardiff Oncology's fundamental ratios, stakeholders can gain valuable insights into Cardiff Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cardiff Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cardiff Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.Things to note about Cardiff Oncology performance evaluation
Checking the ongoing alerts about Cardiff Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardiff Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardiff Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 488 K. Net Loss for the year was (41.44 M) with loss before overhead, payroll, taxes, and interest of (26.72 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures |
- Analyzing Cardiff Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardiff Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Cardiff Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardiff Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardiff Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardiff Oncology's stock. These opinions can provide insight into Cardiff Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |